Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and Pernix Therapeutics Holdings (NASDAQ:PTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitabiliy.

Analyst Ratings

This is a summary of recent ratings for Adamis Pharmaceuticals Corporation and Pernix Therapeutics Holdings, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamis Pharmaceuticals Corporation 0 0 2 0 3.00
Pernix Therapeutics Holdings 0 1 0 0 2.00

Adamis Pharmaceuticals Corporation presently has a consensus target price of $7.50, indicating a potential upside of 64.84%. Given Adamis Pharmaceuticals Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe Adamis Pharmaceuticals Corporation is more favorable than Pernix Therapeutics Holdings.

Volatility and Risk

Adamis Pharmaceuticals Corporation has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Pernix Therapeutics Holdings has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.

Institutional & Insider Ownership

11.5% of Adamis Pharmaceuticals Corporation shares are owned by institutional investors. Comparatively, 15.6% of Pernix Therapeutics Holdings shares are owned by institutional investors. 12.2% of Adamis Pharmaceuticals Corporation shares are owned by insiders. Comparatively, 5.6% of Pernix Therapeutics Holdings shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Adamis Pharmaceuticals Corporation and Pernix Therapeutics Holdings’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamis Pharmaceuticals Corporation -197.55% -87.56% -54.69%
Pernix Therapeutics Holdings -120.56% N/A -37.77%

Valuation & Earnings

This table compares Adamis Pharmaceuticals Corporation and Pernix Therapeutics Holdings’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Adamis Pharmaceuticals Corporation $9.51 million 13.19 -$21.54 million N/A N/A
Pernix Therapeutics Holdings $135.70 million 0.22 $8.63 million ($18.19) -0.15

Pernix Therapeutics Holdings has higher revenue and earnings than Adamis Pharmaceuticals Corporation.

Summary

Pernix Therapeutics Holdings beats Adamis Pharmaceuticals Corporation on 7 of the 12 factors compared between the two stocks.

Adamis Pharmaceuticals Corporation Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Pernix Therapeutics Holdings Company Profile

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.